Kerstin Rhiem

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7022512/publications.pdf

Version: 2024-02-01

68	3,883	186265 28	128289 60
papers	citations	h-index	g-index

75	75	75	5901
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
2	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 1378.	7.1	300
3	Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Journal of Clinical Oncology, 2009, 27, 5887-5892.	1.6	292
4	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncology, The, 2021, 22, 1151-1161.	10.7	248
5	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
6	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
7	Prevalence ofBRCA1/2germline mutations in 21â€...401 families with breast and ovarian cancer. Journal of Medical Genetics, 2016, 53, 465-471.	3.2	179
8	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	1.9	148
9	Gene panel testing of 5589 <scp>BRCA</scp>1/2â€negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancer Medicine, 2018, 7, 1349-1358.	2.8	126
10	Hereditary Breast and Ovarian Cancer. Deutsches Ärzteblatt International, 2011, 108, 323-30.	0.9	119
11	The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Research, 2012, 14, R156.	5.0	112
12	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	2.5	102
13	Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2021, 39, 506-506.	1.6	96
14	High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Research and Treatment, 2019, 175, 217-228.	2.5	94
15	Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer, 2018, 18, 265.	2.6	84
16	Intense dose-dense epirubicin, paclitaxel, cyclophosphamideÂversus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOctoâ€"GBG 84): A randomised phase III trial. European Journal of Cancer, 2019, 106, 181-192.	2.8	84
17	BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Breast Cancer Research, 2018, 20, 7.	5.0	78
18	Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer. JAMA Oncology, 2017, 3, 1245.	7.1	74

#	Article	IF	Citations
19	Germline Mutations in Triple-Negative Breast Cancer. Breast Care, 2017, 12, 15-19.	1.4	59
20	Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. Genetics in Medicine, 2018, 20, 452-457.	2.4	59
21	Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: A prospective cohort study. Gynecologic Oncology, 2006, 103, 1077-1082.	1.4	53
22	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
23	Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. Breast Cancer Research, 2019, 21, 55.	5.0	44
24	Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).. Journal of Clinical Oncology, 2018, 36, 104-104.	1.6	43
25	Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer. JAMA Oncology, 2020, 6, 744.	7.1	42
26	Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort. Breast Journal, 2019, 25, 455-460.	1.0	35
27	GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).. Journal of Clinical Oncology, 2019, 37, 506-506.	1.6	34
28	Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance. International Journal of Cancer, 2020, 146, 999-1009.	5.1	32
29	Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation. European Journal of Health Economics, 2018, 19, 341-353.	2.8	30
30	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26
31	Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. European Journal of Cancer, 2020, 130, 92-101.	2.8	26
32	Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancerâ€"an European consensus statement and expert recommendations. European Journal of Cancer, 2019, 106, 54-60.	2.8	25
33	BRCA1-Associated Breast Carcinomas Frequently Present with Benign Sonographic Features. American Journal of Roentgenology, 2006, 186, E11-E12.	2.2	24
34	Supplemental screening ultrasound increases cancer detection yield in BRCA1 and BRCA2 mutation carriers. Archives of Gynecology and Obstetrics, 2014, 289, 663-670.	1.7	22
35	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
36	Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemiaâ€like phenotype, and no chromosome fragility. Molecular Genetics & Genomic Medicine, 2019, 7, e863.	1.2	22

#	Article	IF	Citations
37	Residual glandular tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies. Surgical Oncology, 2019, 29, 126-133.	1.6	20
38	Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey. Cancer, 2020, 126, 4032-4041.	4.1	20
39	Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making. BMC Medical Informatics and Decision Making, 2021, 21, 180.	3.0	18
40	Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer. European Journal of Health Economics, 2019, 20, 739-750.	2.8	16
41	Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review. Value in Health, 2021, 24, 303-312.	0.3	16
42	A tandem duplication of BRCA1 exons 1â€“19 through DHX8 exon 2 in four families with hereditary breast and ovarian cancer syndrome. Breast Cancer Research and Treatment, 2018, 172, 561-569.	2.5	12
43	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. European Journal of Cancer, 2022, 160, 100-111.	2.8	12
44	Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. Cancers, 2022, 14, 521.	3.7	12
45	A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).. Journal of Clinical Oncology, 2017, 35, 3062-3062.	1.6	11
46	Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature. Oncology Letters, 2018, 15, 4093-4096.	1.8	10
47	Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.. Journal of Clinical Oncology, 2019, 37, 509-509.	1.6	10
48	Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer â€“ Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?. Geburtshilfe Und Frauenheilkunde, 2020, 80, 932-940.	1.8	7
49	Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation â€“ real life data. Gynecologic Oncology, 2021, 163, 569-577.	1.4	7
50	Breast cancer characteristics and surgery among women with Liâ€Fraumeni syndrome in Germanyâ€”A retrospective cohort study. Cancer Medicine, 2021, 10, 7747-7758.	2.8	7
51	Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial. Trials, 2022, 23, 157.	1.6	7
52	Vacuum-assisted breast biopsies (VAB) carried out on an open 1.0 T MR imager: Influence of patient and target characteristics on the procedural and clinical results. European Journal of Radiology, 2016, 85, 1157-1166.	2.6	6
53	Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors. Breast Care, 2022, 17, 208-223.	1.4	6
54	The ticking time-bomb. Health literacy in the context of genetic risk prediction in familial breast-ovarian cancer; A qualitative study. Qualitative Research in Medicine & Healthcare, 2021, 5, .	0.2	5

#	Article	IF	Citations
55	The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance. Current Medical Research and Opinion, 2019, 35, 2103-2110.	1.9	4
56	Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review. Geburtshilfe Und Frauenheilkunde, 2021, 81, 679-698.	1.8	4
57	Medical knowledge and information needs among women with pathogenic variants in moderateâ€risk genes for hereditary breast cancer attending genetic counseling at an academic hospital in Germanyâ€"A qualitative approach. Journal of Genetic Counseling, 2022, 31, 698-712.	1.6	4
58	Nurse-led decision coaching by specialized nurses for healthy BRCA1/2 gene mutation carriersÂ-adaptation and pilot testing of a curriculum for nurses: a qualitative study. BMC Nursing, 2022, 21, 42.	2.5	4
59	Modern day screening for Lynch syndrome in endometrial cancer: the KEM experience. Archives of Gynecology and Obstetrics, 2021, 304, 975-984.	1.7	3
60	Influence of aging and gadolinium exposure on T1, T2, and T2*-relaxation in healthy women with an increased risk of breast cancer with and without prior exposure to gadoterate meglumine at 3.0-T brain MR imaging. European Radiology, 2022, 32, 331-345.	4.5	3
61	Survey on Physiciansâ€™ Knowledge and Training Needs in Genetic Counseling in Germany. Breast Care, 2021, 16, 389-395.	1.4	3
62	Genetic clinicians' confidence in <scp>BOADICEA</scp> comprehensive breast cancer risk estimates and counselees' psychosocial outcomes: A prospective study. Clinical Genetics, 2022, 102, 30-39.	2.0	3
63	Risk-Adjusted Prevention. Perspectives on the Governance of Entitlements to Benefits in the Case of Genetic (Breast Cancer) Risks. Recent Results in Cancer Research, 2021, 218, 47-66.	1.8	2
64	BRCA1/2 mutation prevalence in triple-negative breast cancer patients without family history of breast and ovarian cancer.. Journal of Clinical Oncology, 2016, 34, 1090-1090.	1.6	2
65	â€œYou Always Have It in the Back of Your Mindâ€â€"Feelings, Coping, and Support Needs of Women with Pathogenic Variants in Moderate-Risk Genes for Hereditary Breast Cancer Attending Genetic Counseling in Germany: A Qualitative Interview Study. International Journal of Environmental Research and Public Health, 2022, 19, 3525.	2.6	2
66	Assessment of psychosocial difficulties by genetic clinicians and distress in women at high risk of breast cancer: a prospective study. European Journal of Human Genetics, 2022, 30, 1067-1075.	2.8	2
67	Effect of distress and personality factors on the preference-sensitive decision making of BRCA1/2 mutation carriers on preventive options.. Journal of Clinical Oncology, 2016, 34, 1589-1589.	1.6	1
68	Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany. Breast Care, 2021, 16, 389-395.	1.4	0